Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

1-25 of 41 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2

MASCC/ISOO Clinical Practice Statement: Adjuvant bone-modifying agents in primary breast cancer patients - prevention of medication-related osteonecrosis of the jaw.
Yarom N, Van Poznak CH, Epstein JB, Ottaviani G, Matsuda Y, Migliorati C, Elad S
Support Care Cancer, 32(8):547, 25 Jul 2024
Cited by: 1 article | PMID: 39048887 | PMCID: PMC11269502
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials.
Rugo HS, Van Poznak CH, Neven P, Danielewicz I, Lee SC, Campone M, Chik JYK, Vega Alonso E, Naume B, Brain E, Siegel JM, Li R, Uema D, Wagner VJ, Coleman RE
Breast Cancer Res Treat, 204(2):249-259, 20 Dec 2023
Cited by: 3 articles | PMID: 38123789 | PMCID: PMC10948526
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.
Eisen A, Somerfield MR, Accordino MK, Blanchette PS, Clemons MJ, Dhesy-Thind S, Dillmon MS, D'Oronzo S, Fletcher GG, Frank ES, Hallmeyer S, Makhoul I, Moy B, Thawer A, Wu JY, Van Poznak CH
J Clin Oncol, 40(7):787-800, 18 Jan 2022
Cited by: 34 articles | PMID: 35041467
Add to export list Review
Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer.
Van Poznak CH, Unger JM, Darke AK, Moinpour C, Bagramian RA, Schubert MM, Hansen LK, Floyd JD, Dakhil SR, Lew DL, Wade JL, Fisch MJ, Henry NL, Hershman DL, Gralow J
JAMA Oncol, 7(2):246-254, 01 Feb 2021
Cited by: 18 articles | PMID: 33331905 | PMCID: PMC7747039
Add to export list Free full text in Europe PMC
Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307.
Gralow JR, Barlow WE, Paterson AHG, M'iao JL, Lew DL, Stopeck AT, Hayes DF, Hershman DL, Schubert MM, Clemons M, Van Poznak CH, Dees EC, Ingle JN, Falkson CI, Elias AD, Messino MJ, Margolis JH, Dakhil SR, Chew HK, [...] Hortobagyi GN
J Natl Cancer Inst, 112(7):698-707, 01 Jul 2020
Cited by: 35 articles | PMID: 31693129 | PMCID: PMC7357327
Add to export list Free full text in Europe PMC
Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022.
Freedman RA, Gelman RS, Agar NYR, Santagata S, Randall EC, Gimenez-Cassina Lopez B, Connolly RM, Dunn IF, Van Poznak CH, Anders CK, Melisko ME, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Moy B, Blackwell KL, Puhalla SL, Ibrahim N, [...] Translational Breast Cancer Research Consortium (TBCRC)
Clin Breast Cancer, 20(2):145-151.e2, 22 Aug 2019
Cited by: 14 articles | PMID: 31558424 | PMCID: PMC7035200
Add to export list Free full text in Europe PMC
Phase II randomized controlled trial of hypnosis versus progressive muscle relaxation for body image after breast or gynecologic cancer.
Barton DL, Brooks TM, Cieslak A, Elkins GR, Clark PM, Baydoun M, Smith AB, Van Poznak CH
Breast Cancer Res Treat, 178(2):357-365, 09 Aug 2019
Cited by: 2 articles | PMID: 31399932
Add to export list
Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline.
Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, Migliorati CA, Khan A, Morrison A, Anderson H, Murphy BA, Alston-Johnson D, Mendes RA, Beadle BM, Jensen SB, Saunders DP
J Clin Oncol, 37(25):2270-2290, 22 Jul 2019
Cited by: 131 articles | PMID: 31329513
Add to export list Review
TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.
Freedman RA, Gelman RS, Anders CK, Melisko ME, Parsons HA, Cropp AM, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Connolly RM, Moy B, Van Poznak CH, Blackwell KL, Puhalla SL, Jankowitz RC, Smith KL, Ibrahim N, Moynihan TJ, [...] Translational Breast Cancer Research Consortium
J Clin Oncol, 37(13):1081-1089, 12 Mar 2019
Cited by: 185 articles | PMID: 30860945 | PMCID: PMC6494354
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Dural Cells Release Factors Which Promote Cancer Cell Malignancy and Induce Immunosuppressive Markers in Bone Marrow Myeloid Cells.
Szerlip NJ, Calinescu A, Smith E, Tagett R, Clines KL, Moon HH, Taichman RS, Van Poznak CH, Clines GA
Neurosurgery, 83(6):1306-1316, 01 Dec 2018
Cited by: 3 articles | PMID: 29462368 | PMCID: PMC7191887
Add to export list Free full text in Europe PMC
Use of Bone-Modifying Agents in Myeloma and Bone Metastases: How Recent Dosing Interval Studies Have Affected Our Practice.
Campagnaro E, Reimers MA, Qin A, Alva AS, Schneider BJ, Van Poznak CH
J Oncol Pract, 14(8):457-464, 01 Aug 2018
Cited by: 7 articles | PMID: 30096277
Add to export list Review
Oral health-related concerns, behavior, and communication with health care providers of patients with breast cancer: impact of different treatments.
Taichman LS, Van Poznak CH, Inglehart MR
Spec Care Dentist, 38(1):36-45, 16 Jan 2018
Cited by: 4 articles | PMID: 29337392
Add to export list
Oral Care: Exploring Education, Attitudes, and Behaviors Among Nurses Caring for Patients With Breast Cancer .
Suminski JA, Inglehart M, Munz SM, Van Poznak CH, Taichman LS
Clin J Oncol Nurs, 21(3):371-378, 01 Jun 2017
Cited by: 5 articles | PMID: 28524905
Add to export list
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline.
Dhesy-Thind S, Fletcher GG, Blanchette PS, Clemons MJ, Dillmon MS, Frank ES, Gandhi S, Gupta R, Mates M, Moy B, Vandenberg T, Van Poznak CH
J Clin Oncol, 35(18):2062-2081, 06 Mar 2017
Cited by: 97 articles | PMID: 28618241
Add to export list Review
Dental health status and patient-reported outcomes at baseline in patients participating in the osteonecrosis of the jaw registry study, SWOG S0702.
Van Poznak CH, Darke A, Moinpour CM, Bagramian RA, Schubert MM, Gralow JR, Wade JL, Unger JM
Support Care Cancer, 25(4):1191-1199, 07 Dec 2016
Cited by: 2 articles | PMID: 27928641 | PMCID: PMC5323355
Add to export list Free full text in Europe PMC
Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622.
Schott AF, Barlow WE, Van Poznak CH, Hayes DF, Moinpour CM, Lew DL, Dy PA, Keller ET, Keller JM, Hortobagyi GN
Breast Cancer Res Treat, 159(1):87-95, 30 Jul 2016
Cited by: 24 articles | PMID: 27475087 | PMCID: PMC5021222
Add to export list Free full text in Europe PMC
Self-reported oral health and quality of life of postmenopausal breast cancer survivors on aromatase inhibitors and women without cancer diagnoses: a longitudinal analysis.
Taichman LS, Van Poznak CH, Inglehart MR
Support Care Cancer, 24(11):4815-4824, 25 Jul 2016
Cited by: 7 articles | PMID: 27455851 | PMCID: PMC5614704
Add to export list Free full text in Europe PMC
Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013.
King TA, Lyman JP, Gonen M, Voci A, De Brot M, Boafo C, Sing AP, Hwang ES, Alvarado MD, Liu MC, Boughey JC, McGuire KP, Van Poznak CH, Jacobs LK, Meszoely IM, Krontiras H, Babiera GV, Norton L, Morrow M, Hudis CA
J Clin Oncol, 34(20):2359-2365, 21 Mar 2016
Cited by: 51 articles | PMID: 27001590 | PMCID: PMC4981976
Add to export list Free full text in Europe PMC
Clinical predictors of long-term survival in HER2-positive metastatic breast cancer.
Murthy P, Kidwell KM, Schott AF, Merajver SD, Griggs JJ, Smerage JD, Van Poznak CH, Wicha MS, Hayes DF, Henry NL
Breast Cancer Res Treat, 155(3):589-595, 13 Feb 2016
Cited by: 18 articles | PMID: 26875184 | PMCID: PMC4895232
Add to export list Free full text in Europe PMC
Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.
Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, Blackwell KL, Moy B, Herold C, Liu MC, Lowe A, Agar NY, Ryabin N, Farooq S, Lawler E, [...] Lin NU
J Clin Oncol, 34(9):945-952, 01 Feb 2016
Cited by: 94 articles | PMID: 26834058 | PMCID: PMC5070554
Add to export list Free full text in Europe PMC
Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses.
Hertz DL, Kidwell KM, Thibert JN, Gersch C, Regan MM, Skaar TC, Henry NL, Hayes DF, Van Poznak CH, Rae JM
Mol Oncol, 9(9):1868-1876, 29 Jul 2015
Cited by: 21 articles | PMID: 26276228 | PMCID: PMC4624024
Add to export list Free full text in Europe PMC
Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.
Oesterreich S, Henry NL, Kidwell KM, Van Poznak CH, Skaar TC, Dantzer J, Li L, Hangartner TN, Peacock M, Nguyen AT, Rae JM, Desta Z, Philips S, Storniolo AM, Stearns V, Hayes DF, Flockhart DA
Breast Cancer Res Treat, 154(2):263-273, 04 Nov 2015
Cited by: 18 articles | PMID: 26536870 | PMCID: PMC4807610
Add to export list Free full text in Europe PMC
Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019.
Paoletti C, Li Y, Muñiz MC, Kidwell KM, Aung K, Thomas DG, Brown ME, Abramson VG, Irvin WJ, Lin NU, Liu MC, Nanda R, Nangia JR, Storniolo AM, Traina TA, Vaklavas C, Van Poznak CH, Wolff AC, Forero-Torres A, [...] Translational Breast Cancer Research Consortium (TBCRC)
Clin Cancer Res, 21(12):2771-2779, 16 Mar 2015
Cited by: 52 articles | PMID: 25779948 | PMCID: PMC5521206
Add to export list Free full text in Europe PMC
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer.
Forero-Torres A, Varley KE, Abramson VG, Li Y, Vaklavas C, Lin NU, Liu MC, Rugo HS, Nanda R, Storniolo AM, Traina TA, Patil S, Van Poznak CH, Nangia JR, Irvin WJ, Krontiras H, De Los Santos JF, Haluska P, Grizzle W, [...] Translational Breast Cancer Research Consortium (TBCRC)
Clin Cancer Res, 21(12):2722-2729, 16 Mar 2015
Cited by: 43 articles | PMID: 25779953 | PMCID: PMC6186432
Add to export list Free full text in Europe PMC
Bone health in adults treated with endocrine therapy for early breast or prostate cancer.
Van Poznak CH
Am Soc Clin Oncol Educ Book, e567-74, 01 Jan 2015
Cited by: 4 articles | PMID: 25993224
Add to export list Review

1-25 of 41 results

1 2

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

Partnerships & funding